title: [Pathomorphosis of anxiety disorder in patients with intestinal dysbiosis].
abstract: It is known, that anxiety is one of the most wide-spread mental disorders in-between psychiatric state and it takes part in pathogenesis a lot of somatic diseases as well. At the same time the host bowel microbiota participates in metabolic control of vital human functions such as mood and behavioural reactions. This title connection reveals some new therapeutic opportunity in treatment of psychiatric disorders that based on using with probiotics. In case non-clinically significant anxiety it is claimed to use probiotic (Enterol) however in case clinically significant anxiety it is claimed to use non-benzodiazepine tranquilizer (Stresam).
authors.forename: Iu P
authors.initials: IuP
authors.lastname: Uspenskiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Balukova
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D001519:Behavior / Q000187:drug effects; D006801:Humans; D007410:Intestinal Diseases / Q000150:complications / Q000178:diet therapy / Q000473:pathology / Q000503:physiopathology; D010078:Oxazines / Q000627:therapeutic use*; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D014151:Anti-Anxiety Agents; D010078:Oxazines; C002125:etifoxine